ArticleApplied biochemistry and biotechnology2025
Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Fold-Promoting Mutation and Signal Peptide Screening on Recombinant Glucan 1,4-Alpha-maltohydrolase Secretion in Pichia pastoris.Applied biochemistry and biotechnology · 2025Article
- Tumor Suppressive Role of Hsa-miR-328-3p in Colon Cancer by RegulatingCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miR)-328-3p is believed to have anti-tumor impacts in various human cancers. However, its role in prostate cancer (PCa) is uncertain. In this research, miR-328-3p expression in PCa was reduced. Meanwhile, it was discovered that miR-328-3p directly targeted profilin-1 (PFN1) 3'-untranslated region to negatively modulate PFN1. Elevating miR-328-3p or reducing PFN1 suppressed cell growth, migration, and invasion, and epithelial-mesenchymal transition; overexpression of miR-328-3p or inhibition of PFN1 delayed tumor growth in vivo. Further studies found that PCa patients with advanced T stage or high Gleason score had significantly lower miR-328-3p compared to PCa patients with early stage or low score. In addition, PCa patients with high miR-328-3p had a better prognosis than those with low miR-328-3p. Briefly, this study highlights the clinical and biological role of miR-328-3p as a tumor suppressor miRNA in PCa and explores the downstream mechanisms of miR-328-3p.
Indexed as
Identifiers
39715971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.